HEIDELBERG PHARMA RESEARCH GMBH

Their core work

Heidelberg Pharma Research is a German biotech SME specializing in drug conjugate technologies for targeted cancer therapy. They develop antibody-drug conjugates (ADCs), peptide-drug conjugates (PDCs), and small molecule-drug conjugates that deliver cytotoxic payloads directly to tumor cells while sparing healthy tissue. Their work spans the full conjugation pipeline — from linker chemistry and bioconjugation to antibody engineering and immunotherapy approaches. They contribute industry-grade drug conjugate expertise to academic training networks, bridging pharmaceutical R&D with university research.

What they specialise in

How they've shifted over time

Their early H2020 work (2015–2018) centered on peptide-drug conjugates and NAD-based cancer target discovery — essentially chemical delivery platforms and new biological targets. From 2019 onward, they broadened significantly into antibody-drug conjugates, immunotherapy, and tumor microenvironment biology, while continuing the conjugate theme through "Magicbullet Reloaded." The trajectory shows a clear shift from purely chemical conjugation toward integrating biological and immunological approaches to cancer treatment.

Moving from chemical conjugation platforms toward antibody-based and immunotherapy-integrated approaches, positioning them at the intersection of biologics and targeted drug delivery.

How they like to work

Heidelberg Pharma Research operates exclusively as a participant, never coordinating — consistent with an industry partner contributing specialized drug development expertise to academic-led training networks. All five projects are MSCA Innovative Training Networks, meaning they host and train early-stage researchers while providing industry perspective. With 55 unique consortium partners across 10 countries, they are well-connected but function as a specialist contributor rather than a network hub.

Connected to 55 distinct partners across 10 European countries through MSCA training networks, giving them a broad academic network in cancer research and pharmaceutical sciences. Their consistent participation in ITN consortia means strong ties to universities and research institutes training the next generation of drug development scientists.

What sets them apart

They bring rare industry-side drug conjugate manufacturing and development expertise into academic training consortia — most MSCA-ITN industry partners are large pharma, making a focused SME with deep conjugation know-how particularly valuable. Their progression from MAGICBULLET to Magicbullet Reloaded shows they are a trusted, returning partner in this specific niche. For consortium builders, they offer a credible pharma SME with hands-on ADC/PDC platform experience that can host researchers and provide real-world drug development training.

Highlights from their portfolio

• MAGICBULLET
  Their first and largest H2020 project (EUR 498,433) — established the peptide-drug conjugate training network that later spawned a sequel.
• Magicbullet Reloaded
  Direct sequel expanding from peptide conjugates to small-molecule conjugates, demonstrating the company's long-term commitment and trusted partner status in this research community.
• TACT
  Their most recent project, marking the shift toward antibodies and immunotherapy — signals where the company is heading strategically.